OlympiA

Adjuvant Olaparib for High-Risk gBRCA-Mutant Early Breast Cancer

Paciente / Población Intervención / Exposición Comparación Desenlace

In 1,836 patients with HER2-negative, high-risk early breast cancer and germline BRCA1/2 mutation, one year of adjuvant olaparib reduced invasive disease-free survival events compared with placebo.

1836

Diseño

Double-blind RCT

Desenlace

Invasive disease-free survival

Relevancia

Resultado3-yr iDFS 85.9% vs 77.1% (HR 0.58). 4-yr OS 89.8% vs 86.4% (HR 0.68).

Tutt ANJ, et al. N Engl J Med. 2021;384(25):2394-2405. 10.1056/NEJMoa2105215

Discusión y crítica

First positive PARP-inhibitor trial in (neo)adjuvant breast cancer. Requires upfront germline BRCA testing, including in early-stage disease.